CL2012003011A1 - Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa. - Google Patents

Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa.

Info

Publication number
CL2012003011A1
CL2012003011A1 CL2012003011A CL2012003011A CL2012003011A1 CL 2012003011 A1 CL2012003011 A1 CL 2012003011A1 CL 2012003011 A CL2012003011 A CL 2012003011A CL 2012003011 A CL2012003011 A CL 2012003011A CL 2012003011 A1 CL2012003011 A1 CL 2012003011A1
Authority
CL
Chile
Prior art keywords
acarbose
water soluble
oral disintegration
soluble vehicle
procedure
Prior art date
Application number
CL2012003011A
Other languages
English (en)
Inventor
Axel Schneeweis
Tobias Laich
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2012003011A1 publication Critical patent/CL2012003011A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Comprimido de desintegración por vía oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehículo soluble en agua y un 1-50 % de un vehículo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegración oral que contienen acarbosa.
CL2012003011A 2010-04-27 2012-10-26 Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa. CL2012003011A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10161114 2010-04-27

Publications (1)

Publication Number Publication Date
CL2012003011A1 true CL2012003011A1 (es) 2013-04-19

Family

ID=44344015

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003011A CL2012003011A1 (es) 2010-04-27 2012-10-26 Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa.

Country Status (27)

Country Link
US (1) US20130131003A1 (es)
EP (1) EP2563329B1 (es)
JP (1) JP5944378B2 (es)
KR (1) KR101788350B1 (es)
CN (2) CN106924199A (es)
AU (1) AU2011247642C1 (es)
BR (1) BR112012027303A2 (es)
CA (1) CA2797365A1 (es)
CL (1) CL2012003011A1 (es)
CO (1) CO6640213A2 (es)
CR (1) CR20120548A (es)
CU (1) CU20120152A7 (es)
DO (1) DOP2012000277A (es)
EC (1) ECSP12012279A (es)
ES (1) ES2623025T3 (es)
GT (1) GT201200290A (es)
IL (1) IL222368B (es)
MX (1) MX348865B (es)
MY (1) MY179724A (es)
NZ (1) NZ603199A (es)
PE (1) PE20130403A1 (es)
PH (1) PH12012502139A1 (es)
SG (2) SG10201505844WA (es)
SI (1) SI2563329T1 (es)
TW (1) TWI556823B (es)
UA (1) UA111155C2 (es)
WO (1) WO2011134962A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201100150A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Suda çözünür dozaj formları
WO2013115738A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Micronized acarbose
WO2013115741A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical compositions comprising alpha-glucosidase inhibitor
EP2890370B1 (en) * 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN104013590A (zh) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 一种含阿卡波糖的药物组合物及其制备方法
CA2970991C (en) * 2014-12-17 2021-08-03 Goran Alderborn A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
CN105213341A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种阿卡波糖片及其制备方法
CN113081984B (zh) * 2021-04-19 2023-06-02 北京阳光诺和药物研究股份有限公司 一种阿卡波糖口崩片及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPH10182687A (ja) * 1996-10-21 1998-07-07 Bayer Yakuhin Kk アカルボースの貯蔵安定化法
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
KR100682836B1 (ko) * 2004-12-06 2007-02-15 엘지전자 주식회사 유기 전계 발광 소자
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN101390440B (zh) * 2006-02-27 2012-10-10 松下电器产业株式会社 可穿戴终端、控制可穿戴终端的处理器及方法
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN101411715B (zh) * 2007-10-19 2012-03-28 杭州华东医药集团生物工程研究所有限公司 含有阿卡波糖的药物组合物
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
JP2011506279A (ja) * 2007-12-08 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 経口で分散可能な錠剤
BRPI0821761A2 (pt) * 2007-12-21 2015-06-16 Eurand Inc Composições de comprimidos de desintegração oral de temazepam
EP2299982B1 (de) * 2008-06-20 2018-04-04 Merck Patent GmbH Direkt verpressbare und schnell zerfallende tablettenmatirx

Also Published As

Publication number Publication date
BR112012027303A2 (pt) 2017-10-24
SG184851A1 (en) 2012-11-29
SG10201505844WA (en) 2015-09-29
SI2563329T1 (sl) 2017-05-31
DOP2012000277A (es) 2012-12-15
CN106924199A (zh) 2017-07-07
MX2012012459A (es) 2012-11-21
IL222368B (en) 2018-11-29
EP2563329A2 (en) 2013-03-06
GT201200290A (es) 2014-09-24
US20130131003A1 (en) 2013-05-23
KR20130062926A (ko) 2013-06-13
CO6640213A2 (es) 2013-03-22
JP2013525404A (ja) 2013-06-20
AU2011247642B2 (en) 2015-05-14
JP5944378B2 (ja) 2016-07-05
AU2011247642C1 (en) 2015-11-12
CN102905687A (zh) 2013-01-30
MX348865B (es) 2017-07-03
AU2011247642A1 (en) 2012-11-08
WO2011134962A3 (en) 2012-05-03
ES2623025T3 (es) 2017-07-10
CR20120548A (es) 2013-03-11
TWI556823B (zh) 2016-11-11
TW201141490A (en) 2011-12-01
IL222368A0 (en) 2012-12-31
MY179724A (en) 2020-11-11
UA111155C2 (uk) 2016-04-11
CA2797365A1 (en) 2011-11-03
CU20120152A7 (es) 2014-02-28
PE20130403A1 (es) 2013-04-13
NZ603199A (en) 2014-05-30
EP2563329B1 (en) 2017-04-12
PH12012502139A1 (en) 2022-03-21
WO2011134962A2 (en) 2011-11-03
KR101788350B1 (ko) 2017-10-19
ECSP12012279A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
UY33025A (es) Composicion farmaceutica que comprende un agonista de glp-1 metionina
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
NI201200074A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
BRPI1006825A2 (pt) compostos pró-neurogênicos
LT2611458T (lt) Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
AP2011005857A0 (en) Tablets for combination therapy.
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
BRPI0907916A2 (pt) Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
PH12012502082A1 (en) Combination of active loaded granules with additional actives
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
BR112013018738A2 (pt) novos derivados de tetrahidroquinolina
CL2015000857A1 (es) Una composicion farmaceutica que consiste en una primera capa que comprende metformina y una segunda capa que comprende gemigliptina; su metodo de preparacion, util para la prevencion y el tratamiento de la diabetes.
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos